Eagle Pharmaceuticals (EGRX)

$1.65 -0.15 (-8.33%)
Market Cap 23.38M
Revenue (ttm) 316.61M
Net Income (ttm) 35.64M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 11.26%
Debt to Equity Ratio 0.28
Volume 501
Avg Vol 7,928
Day's Range N/A - N/A
Shares Out 12.99M
Stochastic %K 82%
Beta 0.83
Analysts Strong Buy
Price Target $17.00

Company Profile

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection,...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 201 326 5300
Address:
50 Tice Boulevard, Suite 315, Woodcliff Lake, United States
11thestate
11thestate Aug. 13 at 1:24 PM
When we see a stock like this, we know how many damaged investors are out there. Believe it or not, there’s some good news. $EGRX investors you might be surprised, but you actually have a chance to recover your losses. Don’t miss it: https://11th.com/cases/eagle-investor-suit
0 · Reply
Tresses
Tresses Jul. 31 at 1:14 AM
$EGRX Still mystified re the 'radio silence' on EA-114... CAL-02 as well. But EA-114 was to be approved/ not approved 1st qtr '26. I don't understand how egrx refuses to comment.
1 · Reply
11thestate
11thestate Jul. 30 at 1:24 PM
Shareholders who bought $EGRX between 2022 and 2024 have until October 16, 2026 to file a claim in the $9.5M settlement. The settlement claims that Eagle Pharmaceuticals misled investors about PEMFEXY sales, inventory issues, and related financial reporting. Eligible investors can still submit a claim before the deadline: https://11th.com/cases/eagle-investor-suit
0 · Reply
Freddy7672
Freddy7672 Jul. 13 at 5:50 AM
$EGRX CFO hired for collect salary.. hasn't done sxxt
0 · Reply
11thestate
11thestate Jul. 10 at 1:50 PM
Imagine buying $EGRX at its peak, only to watch it crash like this and then finding out there’s a way to get some money back. To all $EGRX investors out there, we’ve got some important news: a $9.5 million investor settlement is now open for claims from shareholders who purchased shares between 2022 and 2024. You can check if you’re eligible and claim your share: https://11th.com/cases/eagle-investor-suit
0 · Reply
Freddy7672
Freddy7672 Jul. 8 at 7:27 AM
$EGRX Claim dead line Oct 16 2026?? means nothing till Nov??
1 · Reply
Freddy7672
Freddy7672 Jul. 6 at 7:50 PM
$EGRX I guess the CFO what’s his face can kiss his bonus goodbye 
0 · Reply
11thestate
11thestate Jun. 29 at 1:56 PM
Update for $EGRX investors: The $9.5M Eagle Pharmaceuticals investor settlement is now accepting claims. The case claims Eagle misled investors about PEMFEXY demand and failed to disclose inventory issues that later led to a revenue restatement. After the disclosures, $EGRX declined and investors sued. If you purchased $EGRX between 2022 and 2024, you may be eligible to submit a claim before the October 16, 2026 deadline: https://11th.com/cases/eagle-investor-suit
0 · Reply
Freddy7672
Freddy7672 Jun. 19 at 3:23 AM
$EGRX they said to take the tax write off 
0 · Reply
11thestate
11thestate Jun. 17 at 2:40 PM
$EGRX Update: Information on the $9.5M Settlement Payout If you traded Eagle Pharmaceuticals common stock between 2022 and 2024, you may be eligible to participate in the settlement. More information about eligibility and the claims process is available here: https://11th.com/cases/eagle-investor-suit
0 · Reply
Latest News on EGRX
No data available.
11thestate
11thestate Aug. 13 at 1:24 PM
When we see a stock like this, we know how many damaged investors are out there. Believe it or not, there’s some good news. $EGRX investors you might be surprised, but you actually have a chance to recover your losses. Don’t miss it: https://11th.com/cases/eagle-investor-suit
0 · Reply
Tresses
Tresses Jul. 31 at 1:14 AM
$EGRX Still mystified re the 'radio silence' on EA-114... CAL-02 as well. But EA-114 was to be approved/ not approved 1st qtr '26. I don't understand how egrx refuses to comment.
1 · Reply
11thestate
11thestate Jul. 30 at 1:24 PM
Shareholders who bought $EGRX between 2022 and 2024 have until October 16, 2026 to file a claim in the $9.5M settlement. The settlement claims that Eagle Pharmaceuticals misled investors about PEMFEXY sales, inventory issues, and related financial reporting. Eligible investors can still submit a claim before the deadline: https://11th.com/cases/eagle-investor-suit
0 · Reply
Freddy7672
Freddy7672 Jul. 13 at 5:50 AM
$EGRX CFO hired for collect salary.. hasn't done sxxt
0 · Reply
11thestate
11thestate Jul. 10 at 1:50 PM
Imagine buying $EGRX at its peak, only to watch it crash like this and then finding out there’s a way to get some money back. To all $EGRX investors out there, we’ve got some important news: a $9.5 million investor settlement is now open for claims from shareholders who purchased shares between 2022 and 2024. You can check if you’re eligible and claim your share: https://11th.com/cases/eagle-investor-suit
0 · Reply
Freddy7672
Freddy7672 Jul. 8 at 7:27 AM
$EGRX Claim dead line Oct 16 2026?? means nothing till Nov??
1 · Reply
Freddy7672
Freddy7672 Jul. 6 at 7:50 PM
$EGRX I guess the CFO what’s his face can kiss his bonus goodbye 
0 · Reply
11thestate
11thestate Jun. 29 at 1:56 PM
Update for $EGRX investors: The $9.5M Eagle Pharmaceuticals investor settlement is now accepting claims. The case claims Eagle misled investors about PEMFEXY demand and failed to disclose inventory issues that later led to a revenue restatement. After the disclosures, $EGRX declined and investors sued. If you purchased $EGRX between 2022 and 2024, you may be eligible to submit a claim before the October 16, 2026 deadline: https://11th.com/cases/eagle-investor-suit
0 · Reply
Freddy7672
Freddy7672 Jun. 19 at 3:23 AM
$EGRX they said to take the tax write off 
0 · Reply
11thestate
11thestate Jun. 17 at 2:40 PM
$EGRX Update: Information on the $9.5M Settlement Payout If you traded Eagle Pharmaceuticals common stock between 2022 and 2024, you may be eligible to participate in the settlement. More information about eligibility and the claims process is available here: https://11th.com/cases/eagle-investor-suit
0 · Reply
worldslargestpenguin
worldslargestpenguin Jun. 6 at 9:57 PM
$EGRX just doing the math today on the trailing twelve month sales here.....giving $EGRX a gross to net discount of 50% here cause fuck PBMs, Ryanodex is still performing after going generic 24M net, Belrapzo 29M net protected till 2031, Bendeka where the royalty is at did 181M net which is 56M net on the royalty so coming back to us in 2H'2027, and Byfavo did 1.5M net............how is this company endangered? seems like continual mismanagemnt im so pissed.....we got to call Nantahala Capital Management and tell them to get this company in gear, office number is 203-909-6430 tell them you are a shareholder and get their pressure on this situation
0 · Reply
11thestate
11thestate Jun. 3 at 2:16 PM
$EGRX Investor reminder. Eagle Pharmaceuticals investors who purchased shares between August 8, 2022, and October 1, 2024 may be eligible to participate in the company's investor settlement. The settlement claims that investors were misled about the commercial prospects of PEMFEXY. After the company lowered guidance and disclosed weaker-than-expected performance, the stock price declined significantly. If you traded $EGRX during that period, it may be worth reviewing your records and claim: https://11th.com/cases/eagle-investor-suit
0 · Reply
Freddy7672
Freddy7672 May. 23 at 8:07 PM
$EGRX @Tresses @worldslargestpenguin @Tresses • …the final stages to launch oncology drug in Q1 2026, managing 4 business deals (505B2, ANDA), supporting entire commercial portfolio for project improvements and managing complex/worldwide phase 2 clinical study execution. • Coordinated a product launch from end to end for a high visibility and key oncology product working with external development group, CMO, multiple contracts testing labs (CTL) that resulted in successful build of supply for product launch • Perform risk management to minimize project risks: Partner with the Project Lead to drive cross-functional discussions around the risks and mitigation plan with positive mindset and transparently communicated and escalated as appropriate.
2 · Reply
11thestate
11thestate May. 21 at 1:49 PM
Eagle Pharmaceuticals ($EGRX) Settlement Approved – $9.5 million Recovery Available The court has approved the $9.5 million settlement between Eagle Pharmaceuticals and its investors over product performance and financial controls . In 2023, the company was accused of failing to disclose slowing sales caused by excess and expired inventory at a key wholesale customer. Following the disclosure, the stock dropped, and investors filed a lawsuit. The settlement has now been finalized and approved by the court. If you held $EGRX during the relevant period, you can review the details and submit a claim. https://11th.com/cases/eagle-investor-suit
0 · Reply
worldslargestpenguin
worldslargestpenguin May. 15 at 9:48 PM
$EGRX bendeka alone is worth at least $30M when it gets returned to them....hopefully Nantahala puts pressure on them when the stand still expires this year
1 · Reply
11thestate
11thestate May. 8 at 1:47 PM
$EGRX — Eagle Pharmaceuticals Agreed to Settle With Investors Eagle Pharmaceuticals has agreed to settle $9.5 million with investors regarding product performance and financial controls related to its cancer drug PEMFEXY. The agreement has already been submitted to the court for final approval. The settlement aims to compensate affected shareholders. If you purchased $EGRX between August 9, 2022 and October 1, 2024, you may be eligible to file a claim and recover part of your losses. You can review the details and submit your claim here: https://11th.com/cases/eagle-investor-suit
0 · Reply
11thestate
11thestate Apr. 17 at 1:44 PM
$EGRX — Eagle Pharmaceuticals reached a tentative settlement Held between 8/9/2022–10/1/2024? Settlement amount still being finalized but your application will be queued. Eagle promoted its chemo drug PEMFEXY as a revenue driver while a key wholesaler was sitting on expiring inventory. When Eagle restated revenue in May 2023, the stock dropped. Investors sued. A settlement was reached. Waiting for court's final approval. ➡️ Apply here: https://11th.com/cases/eagle-investor-suit
0 · Reply
Luckyluciano
Luckyluciano Apr. 16 at 12:58 PM
$EGRX Are these class acyion lawsuits legit or are they scams?
1 · Reply
11thestate
11thestate Apr. 2 at 2:05 PM
$EGRX investors: a new settlement has been reached! Eagle Pharmaceuticals has agreed to settle claims that it misled investors about the performance of its cancer drug PEMFEXY, hiding inventory problems at a key wholesale customer while continuing to report strong demand. Now, investors who were caught holding the bag have a chance to recover. 🗓️ Class Period: August 9, 2022 – October 1, 2024 ⏳ Settlement terms are still being finalized, but you can submit your early claim now. 👉 Submit your application here: https://11th.com/cases/eagle-investor-suit
0 · Reply
Freddy7672
Freddy7672 Apr. 1 at 9:10 PM
$EGRX Nantahala and the board trying hard to show court there’s no money here strategically
0 · Reply
11thestate
11thestate Mar. 25 at 2:24 PM
A common question: what about legal fees? Here's how it works: attorney fees in $EGRX settlement are approved separately by the court — and are capped by law. They don't come out of your payout. The fund set aside for investors is exactly that — for investors. If you bought between August 9, 2022, and October 1, 2024, what's waiting for you has nothing to do with what the lawyers earn. Check your eligibility here: https://11th.com/cases/eagle-investor-suit
0 · Reply
11thestate
11thestate Mar. 24 at 3:29 PM
This settlement has no impact on $EGRX stock price. Eagle Pharmaceuticals already reached an agreement with investors. The case is closed. The settlement fund doesn't come from current operations — it comes from a legal process that has already concluded. You can still be a shareholder and file a claim at the same time. They're not mutually exclusive. If you bought between August 9, 2022 and October 1, 2024, check if you qualify: https://11th.com/cases/eagle-investor-suit
0 · Reply